Background-Atherosclerotic plaque rupture is accompanied by an acute decrease in the carotid plaque expression of micro-RNAs (miRs)-221 and miR-222. Circular RNA (circR)-284 is a potential inhibitor of miR-221/miR-222 activity. We aimed to determine whether changes in the serum levels of these noncoding RNAs are observed in patients with asymptomatic high-grade carotid disease versus patients with acutely symptomatic carotid disease and recent ischemic stroke. Additionally, we tested the use of functionally related noncoding RNA pairs to enhance the discriminatory power of noncoding RNAs as circulating biomarkers. Methods and Results-Serum levels of miR-221, miR-222, miR-145, and circR-284 were measured in 24 asymptomatic (asymptomatic) and 17 acutely symptomatic patients ([urgent] ischemic cerebrovascular event within the previous 5 days) undergoing carotid endarterectomy. miR-221 was significantly lower, whereas circR-284 was elevated in the serum of the urgent compared with the asymptomatic group. The ratio of serum circR-284:miR-221 was significantly elevated in the urgent group (P=0.0002) and exhibited favorable characteristics as a biomarker indicative of carotid plaque rupture and stroke. A validation study in 112 patients (47 asymptomatic, 41 urgent, and 24 patients with a cerebrovascular event between 5 and 180 days of the carotid endarterectomy [symptomatic]) confirmed elevation of serum circR-284:miR-221 uniquely in the urgent group (P<0.001) and favorable sensitivity and specificity for detecting plaque rupture and stroke. Conclusions-Serum circR-284:miR-221 has potential as a diagnostic biomarker of carotid plaque rupture and stroke.
arly detection of acute ischemic stroke has the potential to reduce morbidity and mortality in patients with advanced carotid atherosclerotic disease. 1 Currently, there is no biomarker predictive of atherosclerotic plaque rupture and stroke. Stable carotid atherosclerotic plaques are characterized by a necrotic core with an overlying fibrous cap composed of VSMCs (vascular smooth muscle cells) in a collagen-rich matrix. 2 The fibrous cap results from intimal thickening in response to arterial inflammation. 3 In vulnerable plaques, the fibrous cap is thinner, exhibiting fewer VSMCs and increased inflammatory cells. Therefore, a promising strategy for developing diagnostics predictive of a future carotid-related ischemic cerebrovascular event (eg, transient ischemic attack and ischemic stroke) is identifying circulating biomarkers indicative of a transition from intimal thickening to fibrous cap thinning.
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Noncoding RNAs (ncRNAs) have emerged as important effectors of intimal thickening and potential circulating biomarkers for cardiovascular disease. [4] [5] [6] Recently, we reported that miR-221 and miR-222, but not miR-145, are reduced in the shoulder region of carotid plaques after an acute ischemic cerebrovascular event.
7 miR-221 and -222 promote intimal thickening through downregulation of p27 Kip1 , a cyclin-dependent kinase inhibitor that inhibits VSMC cell cycle progression. 8, 9 miR-145 inhibits intimal thickening through promotion of VSMC differentiation. 10 A second form of ncRNA, circular RNAs (circR), are formed when the 5′ and 3′ ends of a single RNA strand are spliced. 11 Recently, Memczak et al 12 identified a large number of circRNAs including circR-284 (circbase. org), which possesses an miR-221 and miR-222 binding site and may serve to regulate miR-221/miR-222 activity.
Here, we report that serum miR-221 levels are reduced after plaque rupture, which parallels our recent findings in the carotid plaque. 7 Furthermore, we found that circR-284 is expressed in the carotid plaque and is increased in the sera of patients after plaque rupture. Our data demonstrate that the serum ratio of circulating circR-284 to miR-221 is elevated in patients presenting with an acute carotid-related ischemic Serum circR-284:miR-221 in Plaque Rupture event and has the potential to serve as a diagnostic biomarker for carotid-related cerebrovascular ischemia.
Materials and Methods

Patient Population
Discovery (n=41) and validation (n=112) studies were conducted with serum collected from patients undergoing carotid endarterectomy (CEA) in the Section of Vascular/Endovascular Surgery, Department of Surgery at the Ochsner Clinic. Patients were stratified into 3 groups: (1) those without a previous cerebrovascular event in the previous 6 months (asymptomatic), (2) patients with either an acute stroke or transient ischemic attack within 5 days of the CEA (urgent), and (3) patients who had a more remote cerebrovascular ischemic event within 5 to 180 days of the CEA (symptomatic). The Ochsner Institutional Review Board approved the protocol and informed consent was obtained from all patients.
RNA Isolation and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Analysis
Total RNA was isolated from the serum using the miRNeasy Serum/ Plasma kit (Qiagen Inc., Valencia, CA) with minor modifications. miRNAs were measured using the miScript II RT Kit coupled with the miScript SYBR Green PCR Kit (Qiagen). The catalog numbers for the individual miRNA PCR assays are listed in the Table I 
Droplet Digital PCR
The QX200 ddPCR EvaGreen Supermix (Bio-Rad Laboratories) was used in combination with the primers for miR-221 and circR-284. For measurement of miR-221, the cDNA was prepared in the same manner as above and the entire reaction was used as template, according to the manufacturer's instructions. For measurement of circR-284, a 1-step PCR protocol was used where a reverse transcription step (50°C, 30 minutes) was inserted before the manufacturer's recommended PCR protocol. The PCR was performed on a C1000 Touch Thermal Cycler and the QX200 Droplet Digital PCR system (Bio-Rad Laboratories).
Statistics
Data are expressed as the mean±SEM. Statistical analysis between groups was performed using Student t test or ANOVA coupled with Tukey honest significant difference test. χ 2 analysis was used to compare categorical variables across groups. With 112 patients in the validation study, it was appropriately powered to achieve α=0.05 and β=0.019. Accuracy was calculated as the number of true positives plus false-negatives divided by the total number of samples. All analyses were performed using SPSS version 19.0 (IBM).
Results
Discovery Study Population
Serum levels of miR-145, miR-221, miR-222, and circR-284 were measured in 24 asymptomatic patients and 17 urgent patients while undergoing CEA. In the urgent group, the average time between the cerebrovascular event and CEA was short (2.6±0.3 days) and the average stroke severity was 3.1±1.0 on the National Institutes of Health Stroke Scale, representing minor strokes. There were no significant differences in age, sex, smoking status, body mass index (BMI), lipid panel, use of antiplatelet or anticoagulant therapies, or serum creatinine between the asymptomatic and urgent CEA groups (Table 1) .
Serum miR-221
Recently, we reported that miR-221 and miR-222 are reduced in the carotid plaque shoulder region of patients immediately after an acute plaque rupture and ischemic cerebrovascular event. 7 To determine whether these changes are also reflected in the serum, we compared circulating levels of miR-221, miR-222, and miR-145 in the asymptomatic and urgent groups. MiR-222 and miR-145 were not reliability detected in the majority of our samples. The urgent group exhibited a significantly lower level of miR-221 than the asymptomatic group (0.25±0.11 versus 1.00±0.31; P=0.01; Figure 1A ).
Serum circR-284
As circR-284 has a potential miR-221 binding site ( Figure I in the Data Supplement), it is a potential inhibitor of miR-221 and miR-222, making it a candidate for normalization of miR-221 measurements. We confirmed that circR-284 is expressed in human VSMCs ( Figure II in the Data Supplement) and in carotid plaques (data not shown). Serum circR-284 levels did not exhibit a significant change after an acute carotid plaque rupture-mediated ischemic cerebrovascular event, such as transient ischemic attack or stroke (2.96±1.16 versus 1.00±0.37; P=0.06; Figure 1B ).
Serum circR-284:miR-221
Receiver operator characteristic curve analysis suggested miR-221 levels do not sufficiently discriminate between the asymptomatic and urgent groups to serve as a predictor of plaque rupture. Given the inverse putative functional relationship between miR-221 and circR-284, we tested whether the ratio of circR-284 to miR-221 (circR-284:miR-221) would yield a serum biomarker of a carotid-related cerebrovascular ischemic event. Serum circR-284:miR-221 was significantly higher in the urgent than in the asymptomatic group (11.7±0.48 versus 1.0±0.6; P=0.0002; Figure 1C ). There were not significant differences in serum circR-284:miR-221 with respect to sex, history of smoking, statin use, race, use of antiplatelet or anticoagulant therapies, and presence of chronic kidney disease nor was there a significant correlation between the serum ncRNAs levels and age, BMI, lipid panel, or serum creatinine (Tables II and III in the Data Supplement) . Comparison of the sensitivity, specificity, likelihood ratios, accuracy, and receiver operator characteristic curves of the miR-221 and circR-284:miR-221 tests demonstrates that circ-284:miR-221 has potential as a diagnostic test for carotid plaque rupture leading to an acute ischemic event ( Figure 1D ; Table 2 ).
Validation Study
Next, we sought to validate the use of the ratio of circulating circR-284:miR-221 as a biomarker for the occurrence of an acute ischemic cerebrovascular event after carotid plaque rupture. To do this, we measured circulating miR-221 and circR-284 in an additional set of 48 asymptomatic, 41 urgent, and 24 symptomatic patients using droplet digital PCR. There was no significant difference between the groups for age, BMI, lipids, serum creatinine, use of antiplatelet or anticoagulant therapies, or smoking history and only a significantly greater percentage of males in the urgent group (Table 3) . Compared with both the asymptomatic and symptomatic groups, the urgent group exhibited a trend toward lower serum miR-221 (9.1±0.67 versus 13.2±1.52 and 11.0±2.27 copies/ng of RNA; P=0.10 compared with the asymptomatic and P=0.63 compared with symptomatic; Figure 2A ) and significantly elevated serum circR-284 (31.6±2.09 versus 9.3±1.40 and 10.0±2.89 copies/ng of RNA; P<0.001 for both comparisons; Figure 2B ). Thus, although miR-221 expression is greater than circR-284 expression in the asymptomatic and symptomatic groups, the opposite is true in the urgent group. As expected, these values are orders of magnitude lower than those seen with tissue or cultured VSMCs. Circulating circR-284:miR-221 was highest in the urgents (4.2±0.40 versus 0.6±0.05 and 0.7±0.1, P<0.001 for urgent versus asymptomatic and symptomatic groups; Figure 2C ). Neither were there no significant differences in serum circR-284:miR-221 with respect to sex, history of smoking, statin use, use of antiplatelet or anticoagulant therapies nor was there a significant correlation between the serum ncRNAs levels and BMI, lipid panel, or serum creatinine (Tables IV and V in the Data Supplement). There was a mild but significant correlation between serum circR-284:miR-221 ratio and age (R 2 = 0.04; P=0.05). Multivariable logistic regression confirmed a significant association between a recent carotid Table VI in the Data Supplement) after adjustment for age, sex, serum lipids, serum creatinine, BMI, hypertension, and smoking status. As in the discovery study, comparison of the sensitivity, specificity, likelihood ratios, accuracy, and receiver operator characteristic curves of the miR-221, circR-284, and circR-284:miR-221 levels demonstrate that the circ-284:miR-221 ratio has a greater potential as a diagnostic test for an acute ischemic cerebrovascular event after carotid plaque rupture ( Figure 2D ; Table 4 ).
Discussion
The goal of this study was to determine whether circulating ncRNAs could be used to identify those patients who have experienced a recent carotid-related cerebrovascular ischemic event, allowing for minimization of the time between the event and accurate diagnosis, leading to earlier treatment. Recently, we reported that miR-221 and miR-222 expression in the carotid plaque shoulder region is reduced immediately after a carotid-related ischemic cerebrovascular event. 7 Here, we report that serum levels of miR-221 are decreased after an ischemic cerebrovascular event, comparable to our previous observation in the carotid plaque itself. To overcome the need for normalization of serum ncRNAs, we paired miR-221 with a putatively related ncRNA, circR-284, to achieve a serum biomarker with the potential to address this clinical need.
This report, although focused on the use of these ncRNAs as serum biomarkers of plaque rupture, raises additional questions about the molecular mechanism regulating their expression and secretion to the serum. Our data combined with others confirm that both miR-221 and circR-284 are expressed in VSMCs. 9, 13 Located in different regions of the genome, the expression of these RNAs is likely independent of each other. The proposed relationship between miR-221 and circR-284 is instead based on the presence of a miR-221 binding site in the circR-284 sequence. The presence of this sequence suggests that circR-284 may act as a miR-221 sponge, inhibiting its activity. In addition, the mechanism regulating serum levels of these ncRNAs remains unclear. As a first step in determining whether the carotid plaque itself is the source of the circulating ncRNAs, we have measured both miR-221 and circR-284 in microparticles isolated from cultured VSMCs ( Figure III in the Data Supplement). We are actively examining these issues with ongoing studies in our laboratory.
One characteristic of miR-221 that makes it an attractive candidate for use as a serum biomarker for carotid plaque rupture is that expression in the carotid plaque returns to normal levels within 7 days post-event. 7 Data from the validation study, which included 24 patients with a cerebrovascular event within 5 to 180 days of the CEA (symptomatic), in addition to the 47 asymptomatic and 41 urgent patients, demonstrate that serum miR-221 and circR-284 exhibit a similar temporal pattern as the carotid tissue. These ncRNAs show a trend toward increasing miR-221 and decreasing circR-284 levels in the symptomatic group. Previously, Tsai et al 14 reported a similar, but smaller, decrease in serum miR-221 in patients after a stroke or transient ischemic attack within the previous 7 days. The difference observed is likely because of the shorter time interval between the ischemic cerebrovascular event and sample collection in our study (2.6 days in our study versus ≈7 days for the study of Tsai et al 14 )
. This transient change in expression yields the ability of serum circR-284:mir-221 to discriminate between both asymptomatic and symptomatic 15, 16 Spike-in controls, such as Caenorhabditis elegans miR-39, are commonly used to control for differences in purification efficiencies. This method does not adjust for differences in blood volume. We examined the use of a spike-in control in the discovery study, but this did not enhance our data (data not shown). We then tested whether a potential functionally related ncRNA could, in combination with miR-221, serve as a biomarker of carotid plaque rupture. Although serum circR-284 alone does not seem promising as a biomarker, we demonstrate that the ratio of circR-284 to miR-221 is significantly increased after plaque rupture and exhibits sensitivity and specificity that suggest the ability to discriminate between urgent and asymptomatic patients. Beyond this clinical setting, pairs of functionally related ncRNAs as circulating biomarkers may yield more accurate biomarkers than standard normalization methods.
Minimizing the time between plaque rupture and treatment is critical in reducing the morbidity and mortality in this patient population. Patients diagnosed within 3 hours may be offered systemic thrombolysis with recombinant tissue-type plasminogen activator, which has improved outcomes after stroke. 1 However, tissue-type plasminogen activator utilization rates among patients with acute ischemic stroke is currently only 7% because of delay in diagnosis of >3 hours. 17 New methodologies aimed at creating a point-of-care device for measuring nucleic acids rapidly are being developed. [18] [19] [20] Pairing of such methodologies with our findings could create a rapid diagnostic that would have the potential to minimize diagnostic delays, aid in patient selection for possible thrombolysis, and, henceforth, increase tissue-type plasminogen activator utilization rates, improving outcomes. 
